Literature DB >> 19502378

Blockage of receptor for advanced glycation end products prevents development of cardiac dysfunction in db/db type 2 diabetic mice.

Jan M Nielsen1, Steen B Kristiansen, Rikke Nørregaard, Claus L Andersen, Larry Denner, Torsten T Nielsen, Allan Flyvbjerg, Hans E Bøtker.   

Abstract

AIMS: Activation of the receptor for advanced glycation end products (RAGE) is associated with long-term complications in diabetes mellitus. In this study, we tested whether RAGE activation in the diabetic myocardium is implicated in the development of cardiac dysfunction. METHODS AND
RESULTS: Using MRI and conductance catheter techniques, we evaluated cardiac function in a type 2 diabetic mouse model (db/db), and assessed the effect of blocking RAGE with a RAGE antibody. Gene expressions were evaluated in samples of myocardial tissue. Diabetic db/db mice demonstrated an accelerated age-dependent deterioration in cardiac function associated with altered expression of genes related to cardiac structure and function. Blockage of RAGE signalling prevented the reduction in systolic function (preload recruitable stroke work: 109.8 +/- 13.8 vs. 94.5 +/- 14.9 mmHg/microL, P = 0.04) and development of increased LV diastolic chamber stiffness (0.18 +/- 0.05 vs. 0.27 +/- 0.07 mmHg, P = 0.01). The cardiac expression of collagen (col1a1) was reduced by approximately 45% and the expression of myosin was switched from the foetal isoform (MHCbeta) to the adult isoform (MHCalpha).
CONCLUSION: Activation of RAGE is a significant pathogenetic mechanism for the development of cardiac dysfunction in type 2 diabetes. The underlying mechanisms involve not only the passive biophysical properties of the myocardium but also myocyte function.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19502378     DOI: 10.1093/eurjhf/hfp070

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  27 in total

1.  S100/Calgranulin-mediated inflammation accelerates left ventricular hypertrophy and aortic valve sclerosis in chronic kidney disease in a receptor for advanced glycation end products-dependent manner.

Authors:  Ling Yan; Liby Mathew; Bijoy Chellan; Brandon Gardner; Judy Earley; Tipu S Puri; Marion A Hofmann Bowman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-05-22       Impact factor: 8.311

Review 2.  Implication of advanced glycation end products (Ages) and their receptor (Rage) on myocardial contractile and mitochondrial functions.

Authors:  Remi Neviere; Yichi Yu; Lei Wang; Frederic Tessier; Eric Boulanger
Journal:  Glycoconj J       Date:  2016-06-08       Impact factor: 2.916

Review 3.  Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications.

Authors:  Ravichandran Ramasamy; Shi Fang Yan; Ann Marie Schmidt
Journal:  Ann N Y Acad Sci       Date:  2011-12       Impact factor: 5.691

Review 4.  Receptor for advanced glycation end products (RAGE) and implications for the pathophysiology of heart failure.

Authors:  Ravichandran Ramasamy; Ann Marie Schmidt
Journal:  Curr Heart Fail Rep       Date:  2012-06

Review 5.  Diabetes-induced alterations in the extracellular matrix and their impact on myocardial function.

Authors:  Brittany Law; Vennece Fowlkes; Jack G Goldsmith; Wayne Carver; Edie C Goldsmith
Journal:  Microsc Microanal       Date:  2012-01-05       Impact factor: 4.127

6.  Advanced glycation end-product expression is upregulated in the gastrointestinal tract of type 2 diabetic rats.

Authors:  Peng-Min Chen; Hans Gregersen; Jing-Bo Zhao
Journal:  World J Diabetes       Date:  2015-05-15

7.  Heart rate reduction by If-inhibition improves vascular stiffness and left ventricular systolic and diastolic function in a mouse model of heart failure with preserved ejection fraction.

Authors:  Jan-Christian Reil; Mathias Hohl; Gert-Hinrich Reil; Henk L Granzier; Mario T Kratz; Andrey Kazakov; Peter Fries; Andreas Müller; Matthias Lenski; Florian Custodis; Stefan Gräber; Gerd Fröhlig; Paul Steendijk; Hans-Ruprecht Neuberger; Michael Böhm
Journal:  Eur Heart J       Date:  2012-07-24       Impact factor: 29.983

Review 8.  Advanced glycation end products: role in pathology of diabetic cardiomyopathy.

Authors:  Vijaya Lakshmi Bodiga; Sasidhar Reddy Eda; Sreedhar Bodiga
Journal:  Heart Fail Rev       Date:  2014-01       Impact factor: 4.214

9.  Treatment with brain natriuretic peptide prevents the development of cardiac dysfunction in obese diabetic db/db mice.

Authors:  Eric Plante; Ahmed Menaouar; Bogdan A Danalache; Tom L Broderick; Marek Jankowski; Jolanta Gutkowska
Journal:  Diabetologia       Date:  2014-03-05       Impact factor: 10.122

Review 10.  Diabetes-associated cardiac fibrosis: Cellular effectors, molecular mechanisms and therapeutic opportunities.

Authors:  Ilaria Russo; Nikolaos G Frangogiannis
Journal:  J Mol Cell Cardiol       Date:  2015-12-15       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.